With distribution as a common bottleneck to the sustainable commercialization of innovation, value-added capital is often critical to enable steady progress in the translation of brain science from lab to life. This is especially true in non-medical areas, which lack appropriate infrastructure to commercialize and distribute innovative solutions. What can innovators learn from Discovery’s investment in Lumosity, AAA’s partnership with Posit Science, and Emotiv’s Kickstarter crowdfunding campaign?
- Chair: Matthew Bishop, US Business Editor and New York Bureau Chief of The Economist, YGL Class of 2005
- Dan Fox, Senior VP Corporate Development at Discovery Communications
- Jeff Zimman, Chairman of Posit Science
- Tan Le, CEO of Emotiv Lifesciences, YGL Class of 2009